NYSE · Pharmaceutical Preparations

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb's next earnings date, recent SEC filings, insider trades and reported financials, with end-of-day prices. Every number carries its date and source.

Last close

$63.88

+1.57% 1 day+47.2% 52 weeks

As of Sep 28, 2026, end of day (IEX). Not a live quote.

BMY · one year of daily closes

Sep 25, 2025 to Sep 28, 2026 · end of day · IEX

BMY daily closing prices from Sep 25, 2025 to Sep 28, 2026: low $42.64, high $68.07, last $63.88. End of day, IEX.

Closing prices, split-adjusted, from trades on the IEX exchange (published the next trading day). Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Key facts

1-day change
+1.57%
From $62.89 the session before
52-week change
+47.2%
Close vs close ~252 sessions earlier
52-week range
$42.64–$68.07
Lowest and highest closing prices
Market cap
$130.5B
Last close × shares outstanding (SEC)
Revenue (TTM)
$49.2B
12 months to Jun 30, 2026
Net income (TTM)
$9.3B
12 months to Jun 30, 2026
Diluted EPS (TTM)
$4.54
12 months to Jun 30, 2026

Financials: trailing twelve months from Bristol-Myers Squibb’s reported US-GAAP figures, SEC EDGAR XBRL company facts, period ended Jun 30, 2026.

Recent SEC filings

  1. Jul 30, 202610-QQuarterly report for the period ended Jun 30, 2026
  2. Jul 30, 20268-KCurrent report: Earnings results; Regulation FD disclosure
  3. May 8, 20268-KCurrent report: Shareholder vote results
  4. Apr 30, 202610-QQuarterly report for the period ended Mar 31, 2026
  5. Apr 30, 20268-KCurrent report: Earnings results; Regulation FD disclosure
  6. Mar 25, 2026DEF 14AProxy statement for a shareholder meeting
  7. Feb 11, 202610-KAnnual report for fiscal year ended Dec 31, 2025
  8. Feb 5, 20268-KCurrent report: Earnings results; Regulation FD disclosure

Source: SEC EDGAR. Each line is written from the form type and the official 8-K item titles; open the filing for the full text. All BMY filings on EDGAR

Next earnings

~Oct 29, 2026Estimated

Past results were usually filed before the open

Estimated from past filing dates. Bristol-Myers Squibb hasn't announced this date; Vero projects it from the rhythm of its past SEC filings, so treat it as approximate.

Estimated from SEC EDGAR filing dates

Insider activity (last 90 days)

Open-market buys
0
filings · 0 shares
Open-market sales
2
filings · 6,749 shares

Source: SEC EDGAR Form 4, filed in the 90 days to Oct 1, 2026. Counts are filings with at least one open-market purchase (P) or sale (S); grants, option exercises, tax withholding and gifts are left out.

Insider share counts and prices are as reported on Form 4.

With a free Vero account

What Vero tracks about Bristol-Myers Squibb

Each new Bristol-Myers Squibb filing and headline, summarized in plain English and scored 1–10 for how much it matters. Write down why you own BMY, and Vero reads every new item against those reasons: confirms, challenges or breaks. Alerts say when something crosses the line you set.

Track BMY freeWrite a thesis on BMY

The free plan follows 3 stocks, with no card and no end date.

Bristol-Myers Squibb (BMY): questions, answered from the data

When is Bristol-Myers Squibb's next earnings date?
Around Oct 29, 2026 (past results were usually filed before the open), but that is an estimate, not a date Bristol-Myers Squibb has announced. Estimated from past filing dates: Vero projects it from the dates of Bristol-Myers Squibb's past SEC filings (source: Estimated from SEC EDGAR filing dates). Treat it as approximate until the company confirms it.
What was BMY's last closing price?
BMY closed at $63.88 on Sep 28, 2026. This is an end-of-day price from trades on the IEX exchange, published the next trading day, not a live quote, and it can differ slightly from the consolidated official close. That was +1.57% from the session before and +47.2% over 52 weeks.
Have Bristol-Myers Squibb insiders bought or sold shares recently?
In the 90 days to Oct 1, 2026, SEC Form 4 shows 0 filings with open-market purchases (0 shares) and 2 filings with open-market sales (6,749 shares). The most recent: Massacesi Cristian (EVP,Chief Med Offr,Head of Dev) reported selling 6,249 shares, filed Sep 10, 2026. Grants, option exercises and tax withholding are not counted. Insider share counts and prices are as reported on Form 4.
What did Bristol-Myers Squibb file with the SEC most recently?
A 10-Q filed on Jul 30, 2026: Quarterly report for the period ended Jun 30, 2026. Before that, an 8-K on Jul 30, 2026 and an 8-K on May 8, 2026. Each filing is linked to the original on SEC EDGAR.
Is this page a recommendation to buy or sell BMY?
No. It reports public data (end-of-day prices from IEX and filings from SEC EDGAR) with the date of each. Vero is a research tool, not a financial adviser, and nothing here is a recommendation to buy or sell any security.

Related by SEC industry code

Closes are end of day (IEX), as of each page’s date. Grouped by SEC industry code (SIC).

Prices: IEX HIST end-of-day bars, published the next trading day; never live. Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Filings, Form 4 and financials: Source: SEC EDGAR. Earnings dates: Vero’s calendar, marked confirmed or estimated.

Vero is a research tool, not a financial adviser. Nothing on this site is financial advice or a recommendation to buy or sell any security.

Data as of Oct 1, 2026.